Palliative Care Plays Important Role in Advanced Cancers
Kavitha Ramchandran, MD, discusses the role of palliative care for patients with cancer, particularly those with advanced stage disease.
Watch
Early Trials in Melanoma Show Better Response After 1 Year
Richard D. Carvajal, MD, discusses 2 therapies in clinical trials registering patients with melanoma.
BTK Inhibitors Improve Responses Relapsed/Refractory Mantle Cell Lymphoma
Andre Goy, MD, discusses the different BTK inhibitors as treatment of patients with relapsed/refractory mantle cell lymphoma.
Investigators Study JAK Inhibitors in Patients With Myelofibrosis
Ruben Mesa, MD, discusses the role of JAK inhibitors, which are currently being investigated in patients with myelofibrosis. He also spoke to what the future of this treatment landscape may be.
Novel Approaches for Stage I HER2+ Breast Cancer
The ExteNET Study & Management of HER2+ Breast Cancer
Adjuvant T-DM1 Therapy for Early-Stage HER2+ Breast Cancer
The APHINITY Trial in Early-Stage HER2+ Breast Cancer
Neoadjuvant T-DM1 in Early-Stage HER2+ Breast Cancer
HER2 Heterogeneity and Neoadjuvant Therapy in Breast Cancer
Neoadjuvant Approaches for Early-Stage HER2+ Breast Cancers
HER2 Assessment in Breast Cancer
Update on HER2-Targeted Therapy in Early Breast Cancer
Sara M. Tolaney, MD, MPH, discusses newer approaches to managing early stages of HER2+ breast cancer in both the neoadjuvant and adjuvant spaces.
Treating CLL With BTK Inhibition: Next Steps
Resistance to BTK Targeted Therapy in CLL
BTK Inhibition in CLL: Real-World Data
Combination Therapies With BTK Targeted Therapy in CLL
Long-Term Experience With BTK Inhibitors for CLL
BTK Inhibitors for Elderly Patients With CLL
MRD and 11q Deletions in CLL
Selecting Frontline Therapy for CLL
Acalabrutinib Treatment Considerations in CLL
Acalabrutinib Versus Ibrutinib for CLL
BTK-Targeted Therapy for CLL
Expanding Options for Treatment of CLL Using BTK Inhibitors
Jennifer R. Brown, MD, PhD, and Alan Skarbnik, MD, describe the rationale for treating chronic lymphocytic leukemia with BTK inhibition, and explore current trends in data that impact treatment selection.
Cabazitaxel Impacts Sequencing Strategies in Prostate Cancer
Daniel J. George, MD, discusses how cabazitaxel can impact the sequencing approaches physicians use to treat patients with metastatic castration-resistant prostate cancer.
Immunotherapy Advances the Treatment Landscape of Endometrial Cancers
Shannon N. Westin, MD, MPH, FACOG, discusses the evolving role of immunotherapy as treatment of patients with endometrial cancer.
Evaluating Current Challenges in Hepatocellular Carcinoma
Anjana Pillai, MD, discusses challenges for treating patients with hepatocellular carcinoma.
Future Directions for R/R DLBCL
L-MIND Study: R/R DLBCL